Compare Eversource Energy (D/B/A) Common Stock (ES) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eversource Energy (D/B/A) Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Eversource Energy (D/B/A) Common Stock trades at $66.67 (market cap $25.11B), while Inovio Pharmaceuticals Inc trades at $1.18 (market cap $101.95M). The key difference: Eversource Energy (D/B/A) Common Stock is far larger — about 246.3× Inovio Pharmaceuticals Inc's market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.72% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eversource Energy (D/B/A) Common Stock for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| ES | INO | |
|---|---|---|
Market Cap | $25.11B | $101.95M |
Volume | 3,164,400 | 2,985,847 |
Sector | Utilities | Health |
52-Week High | $76.21 | $2.60 |
52-Week Low | $63.28 | $0.66 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $55.18B | $73.28M |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal and negative financial metrics including a net income margin of -130,000%. The company shows consistent quarterly earnings beats but faces significant cash burn, with operating cash flow negative at -$88.63M in 2025. Key near-term catalyst is the FDA decision on INO-3107 expected by October 30, 2026.
INO presents high-risk speculative opportunity with analyst consensus price target of $2.75 representing 175% upside potential. The investment case hinges on successful FDA approval and commercialization of INO-3107, but carries substantial risk from persistent losses, negative cash flow, and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
